View:
Download DOC
Download PDF
Download XLS
8-K

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

 

FORM 8-K

 

 

CURRENT REPORT

Pursuant to Section 13 or 15(d)

of the Securities Exchange Act of 1934

Date of Report (Date of earliest event Reported): January 13, 2020

 

 

Cytokinetics, Incorporated

(Exact Name of Registrant as Specified in Charter)

 

 

 

Delaware   000-50633   94-3291317

(State or Other Jurisdiction

of Incorporation)

  

(Commission

File Number)

  

(I.R.S. Employer

Identification Number)

280 East Grand Avenue, South San Francisco, California 94080

(Address of Principal Executive Offices) (Zip Code)

(650) 624-3000

(Registrant’s telephone number, including area code)

Not Applicable

(Former name or former address, if changed since last report)

 

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

 

☐

Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

 

☐

Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

 

☐

Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

 

☐

Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

 

Title of each class

  

Trading

Symbol(s)

  

Name of each exchange

on which registered

Common Stock, par value $0.001   CYTK   The Nasdaq Stock Market LLC

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company  ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.  ☐

 

 

 

Item 2.02

Results of Operations and Financial Condition.

On January 13, 2020, in advance of meetings at the 38th Annual J.P. Morgan Healthcare Conference in San Francisco, California, Cytokinetics, Incorporated is making publicly available a corporate presentation that includes preliminary estimates of certain operating and financial results as of and for the year ended December 31, 2019, as well as other updates regarding its business. A copy of the presentation is furnished as Exhibit 99.1 hereto.

The information in this Item 2.02 and the exhibit hereto are being furnished and shall not be deemed to be “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liability of that section, nor shall they be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly set forth by specific reference in such a filing.

 

Item 9.01.

Financial Statements and Exhibits.

(d) Exhibits.

 

Exhibit

Number

   

Description

99.1    Presentation of Cytokinetics, Incorporated, made available on January 13, 2020.

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

    CYTOKINETICS, INCORPORATED
Date: January 13, 2020     By:  

/s/ Ching Jaw

      Ching Jaw
      Senior Vice President, Chief Financial Officer
EX-99.1

Exhibit 99.1 Sarcomere Directed Therapies EMPOWERING MUSCLE EMPOWERING LIVES John, diagnosed with heart failure Jillian, diagnosed with HCM Chuck, diagnosed with ALSExhibit 99.1 Sarcomere Directed Therapies EMPOWERING MUSCLE EMPOWERING LIVES John, diagnosed with heart failure Jillian, diagnosed with HCM Chuck, diagnosed with ALS

Forward-Looking Statements This Presentation contains forward-looking statements for purposes of the Private Securities Litigation Reform Act of 1995 (the “Act”). Cytokinetics disclaims any intent or obligation to update these forward-looking statements, and claims the protection of the Act's Safe Harbor for forward-looking statements. Examples of such statements include, but are not limited to, statements relating to Cytokinetics’ and its partners’ research and development activities; the design, timing, results, significance and utility of preclinical study results, including Cytokinetics’ expectations regarding the timing or results from the clinical trials of omecamtiv mecarbil, reldesemtiv and CK-274; projections regarding growing prevalence, low survival rates and market opportunity in heart failure; Cytokinetics’ commercial readiness for omecamtiv mecarbil; Cytokinetics’ ability to earn and receive milestone payments; the timing and results of clinical trials of AMG 594 and CK-274; the timing of any potential commercial launch of our product candidates, if approved; commercial opportunities for our product candidates; Cytokinetics’ cash runway and 2019 financial guidance; interactions with the FDA; the properties, potential benefits and commercial potential of CK-274, omecamtiv mecarbil, AMG 594, reldesemtiv and Cytokinetics’ other drug candidates. Such statements are based on management's current expectations; but actual results may differ materially due to various risks and uncertainties, including, but not limited to, potential difficulties or delays in the development, testing, regulatory approvals for trial commencement, progression or product sale or manufacturing, or production of Cytokinetics’ drug candidates that could slow or prevent clinical development or product approval, including risks that current and past results of clinical trials or preclinical studies may not be indicative of future clinical trial results, patient enrollment for or conduct of clinical trials may be difficult or delayed, Cytokinetics’ drug candidates may have adverse side effects or inadequate therapeutic efficacy, the FDA or foreign regulatory agencies may delay or limit Cytokinetics’ or its partners’ ability to conduct clinical trials, and Cytokinetics may be unable to obtain or maintain patent or trade secret protection for its intellectual property; Astellas’ or Amgen’s decisions with respect to the design, initiation, conduct, timing and continuation of development activities for reldesemtiv or omecamtiv mecarbil, respectively; Cytokinetics may incur unanticipated research, development and other costs or be unable to obtain financing necessary to conduct development of its products; standards of care may change, rendering Cytokinetics’ drug candidates obsolete; competitive products or alternative therapies may be developed by others for the treatment of indications Cytokinetics’ drug candidates and potential drug candidates may target; and risks and uncertainties relating to the timing and receipt of payments from its partners, including milestones and royalties on future potential product sales under Cytokinetics’ collaboration agreements with such partners. For further information regarding these and other risks related to Cytokinetics’ business, investors should consult Cytokinetics’ filings with the Securities and Exchange Commission. O V E R V I E W C A R D I A C C A N D I D A T E S S K E L E T A L C A N D I D A T E S C O R P O R A T E P R O F I L E 2Forward-Looking Statements This Presentation contains forward-looking statements for purposes of the Private Securities Litigation Reform Act of 1995 (the “Act”). Cytokinetics disclaims any intent or obligation to update these forward-looking statements, and claims the protection of the Act's Safe Harbor for forward-looking statements. Examples of such statements include, but are not limited to, statements relating to Cytokinetics’ and its partners’ research and development activities; the design, timing, results, significance and utility of preclinical study results, including Cytokinetics’ expectations regarding the timing or results from the clinical trials of omecamtiv mecarbil, reldesemtiv and CK-274; projections regarding growing prevalence, low survival rates and market opportunity in heart failure; Cytokinetics’ commercial readiness for omecamtiv mecarbil; Cytokinetics’ ability to earn and receive milestone payments; the timing and results of clinical trials of AMG 594 and CK-274; the timing of any potential commercial launch of our product candidates, if approved; commercial opportunities for our product candidates; Cytokinetics’ cash runway and 2019 financial guidance; interactions with the FDA; the properties, potential benefits and commercial potential of CK-274, omecamtiv mecarbil, AMG 594, reldesemtiv and Cytokinetics’ other drug candidates. Such statements are based on management's current expectations; but actual results may differ materially due to various risks and uncertainties, including, but not limited to, potential difficulties or delays in the development, testing, regulatory approvals for trial commencement, progression or product sale or manufacturing, or production of Cytokinetics’ drug candidates that could slow or prevent clinical development or product approval, including risks that current and past results of clinical trials or preclinical studies may not be indicative of future clinical trial results, patient enrollment for or conduct of clinical trials may be difficult or delayed, Cytokinetics’ drug candidates may have adverse side effects or inadequate therapeutic efficacy, the FDA or foreign regulatory agencies may delay or limit Cytokinetics’ or its partners’ ability to conduct clinical trials, and Cytokinetics may be unable to obtain or maintain patent or trade secret protection for its intellectual property; Astellas’ or Amgen’s decisions with respect to the design, initiation, conduct, timing and continuation of development activities for reldesemtiv or omecamtiv mecarbil, respectively; Cytokinetics may incur unanticipated research, development and other costs or be unable to obtain financing necessary to conduct development of its products; standards of care may change, rendering Cytokinetics’ drug candidates obsolete; competitive products or alternative therapies may be developed by others for the treatment of indications Cytokinetics’ drug candidates and potential drug candidates may target; and risks and uncertainties relating to the timing and receipt of payments from its partners, including milestones and royalties on future potential product sales under Cytokinetics’ collaboration agreements with such partners. For further information regarding these and other risks related to Cytokinetics’ business, investors should consult Cytokinetics’ filings with the Securities and Exchange Commission. O V E R V I E W C A R D I A C C A N D I D A T E S S K E L E T A L C A N D I D A T E S C O R P O R A T E P R O F I L E 2

Sarcomere Directed Therapies OUR MISSION To bring forward new medicines to improve the healthspan of people with devastating cardiovascular and neuromuscular diseases of impaired muscle function. 3Sarcomere Directed Therapies OUR MISSION To bring forward new medicines to improve the healthspan of people with devastating cardiovascular and neuromuscular diseases of impaired muscle function. 3

Heart Failure: Growing Prevalence and Low Survival Rates 6 million people have heart failure in the United States Prevalence Expected to HF Survival Rates Worse than Some Increase by 46% from 2012 – 2030 Prevalent Cancers Men Women 10 9 8 7 6 +46% 5 8.3 4 3 5.7 2 1 0 2012 2030 Mozzafarian, et al. Circulation 2016; 133: e38-360 Mamas et al. Eur J Heart Fail. 2017 Sep;19(9):1095-104 O V E R V I E W C A R D I A C C A N D I D A T E S S K E L E T A L C A N D I D A T E S C O R P O R A T E P R O F I L E 4 Number of cases (M)Heart Failure: Growing Prevalence and Low Survival Rates 6 million people have heart failure in the United States Prevalence Expected to HF Survival Rates Worse than Some Increase by 46% from 2012 – 2030 Prevalent Cancers Men Women 10 9 8 7 6 +46% 5 8.3 4 3 5.7 2 1 0 2012 2030 Mozzafarian, et al. Circulation 2016; 133: e38-360 Mamas et al. Eur J Heart Fail. 2017 Sep;19(9):1095-104 O V E R V I E W C A R D I A C C A N D I D A T E S S K E L E T A L C A N D I D A T E S C O R P O R A T E P R O F I L E 4 Number of cases (M)

High Mortality and Hospital Readmission Rates 1,2 Acute heart failure is the most frequent cause of hospitalization in people > 65 5 years 3,7,8 post-discharge 1 year 7,9 post-discharge ~ 40-50% 60 days mortality 7 post-discharge ~ 20-30% after 5 years Initial mortality Hospitalization ~ 25-50% 1 of 2 after 1 year of patients expire or hospitalized are re-hospitalized HF patients are readmitted 5 within 6 months <1 month <6 months <12 months 4,6 5 3,10 post-discharge post-discharge post-discharge 24% 44% 66% readmitted readmitted readmitted 1, Adams et al. Am Heart J 2006; 149:209-16 6. Krumholz et al. Circ Cardiovasc Qual Outcomes 2009;2(5):407-13 2. Chen et al. JAMA 2011;306:1669-78 7. Loehr et al. Am J Cardiol 2008;101:1016-22 3. Dickstein et al. Eur Heart J 2008;29:2388-442 8. Roger et al. Circulation 2012;125:32-220 4. Korda,, et al. BMC Health Serv Res. 2017;21;17(1):220. 9. Shahar, et al. J Card Fail 2004; 10(5):374-9 5. Krumholz et al. Arch Intern Med 1997;15799 – 105 10. Whellan et al. Circulation 2010 Jan;3(1):33-40 O V E R V I E W C A R D I A C C A N D I D A T E S S K E L E T A L C A N D I D A T E S C O R P O R A T E P R O F I L E 5High Mortality and Hospital Readmission Rates 1,2 Acute heart failure is the most frequent cause of hospitalization in people > 65 5 years 3,7,8 post-discharge 1 year 7,9 post-discharge ~ 40-50% 60 days mortality 7 post-discharge ~ 20-30% after 5 years Initial mortality Hospitalization ~ 25-50% 1 of 2 after 1 year of patients expire or hospitalized are re-hospitalized HF patients are readmitted 5 within 6 months <1 month <6 months <12 months 4,6 5 3,10 post-discharge post-discharge post-discharge 24% 44% 66% readmitted readmitted readmitted 1, Adams et al. Am Heart J 2006; 149:209-16 6. Krumholz et al. Circ Cardiovasc Qual Outcomes 2009;2(5):407-13 2. Chen et al. JAMA 2011;306:1669-78 7. Loehr et al. Am J Cardiol 2008;101:1016-22 3. Dickstein et al. Eur Heart J 2008;29:2388-442 8. Roger et al. Circulation 2012;125:32-220 4. Korda,, et al. BMC Health Serv Res. 2017;21;17(1):220. 9. Shahar, et al. J Card Fail 2004; 10(5):374-9 5. Krumholz et al. Arch Intern Med 1997;15799 – 105 10. Whellan et al. Circulation 2010 Jan;3(1):33-40 O V E R V I E W C A R D I A C C A N D I D A T E S S K E L E T A L C A N D I D A T E S C O R P O R A T E P R O F I L E 5

High Economic Burden of Heart Failure 1,2 Heart failure costs ~$123 billion annually, representing 33% of total Medicare budget Inpatient Admission Rates for HF Patients 1 6X Higher than Non-HF Patients 1800 1600 1400 1200 Heart failure is the most 1000 frequent diagnosis for 1,664 800 hospitalized Medicare 6X 1,2 600 patients in the US 400 200 272 0 Non-Heart Failure Heart Failure 1. Milliman Analysis of Medicare 5% Sample 2011-2012 (2012 index year, 2011 look back year) 2. Milliman Analysis of Medicare 5% Sample (2014 index year, 2013 look back year) and Office of the Actuary 2016 Board of Trustees Report. The costs only include Part A & B costs O V E R V I E W C A R D I A C C A N D I D A T E S S K E L E T A L C A N D I D A T E S C O R P O R A T E P R O F I L E 6 Annual Inpatient Admits per 1,000High Economic Burden of Heart Failure 1,2 Heart failure costs ~$123 billion annually, representing 33% of total Medicare budget Inpatient Admission Rates for HF Patients 1 6X Higher than Non-HF Patients 1800 1600 1400 1200 Heart failure is the most 1000 frequent diagnosis for 1,664 800 hospitalized Medicare 6X 1,2 600 patients in the US 400 200 272 0 Non-Heart Failure Heart Failure 1. Milliman Analysis of Medicare 5% Sample 2011-2012 (2012 index year, 2011 look back year) 2. Milliman Analysis of Medicare 5% Sample (2014 index year, 2013 look back year) and Office of the Actuary 2016 Board of Trustees Report. The costs only include Part A & B costs O V E R V I E W C A R D I A C C A N D I D A T E S S K E L E T A L C A N D I D A T E S C O R P O R A T E P R O F I L E 6 Annual Inpatient Admits per 1,000

Significant Unmet Need in HFrEF Proprietary market research suggests need for novel therapy Market research Drugs that Drugs that Disease Drugs that do Drugs that suggests need do not affect enhance cardiac modifying not affect BP increase QoL for novel therapy renal function performance therapies Physicians say newly Most physicians BP often limiting factor Need drugs that target Need drugs that safely Patient management approved therapies recognize negative effect for up titration and novel/more specific enhance contractility will improve with drugs have prolonged survival, therapies such as therapy initiation molecular targets that increase QoL Increased EF most decreased hospital aldosterone antagonists Need efficacious drugs Need targets other than frequently mentioned Patient QoL decreases visits, but still see need have on renal function that do not result in the neurohormonal desired measure as they lose the ability to for other therapies hypotension pathway; perform daily tasks that reduce mortality O V E R V I E W C A R D I A C C A N D I D A T E S S K E L E T A L C A N D I D A T E S C O R P O R A T E P R O F I L E 7Significant Unmet Need in HFrEF Proprietary market research suggests need for novel therapy Market research Drugs that Drugs that Disease Drugs that do Drugs that suggests need do not affect enhance cardiac modifying not affect BP increase QoL for novel therapy renal function performance therapies Physicians say newly Most physicians BP often limiting factor Need drugs that target Need drugs that safely Patient management approved therapies recognize negative effect for up titration and novel/more specific enhance contractility will improve with drugs have prolonged survival, therapies such as therapy initiation molecular targets that increase QoL Increased EF most decreased hospital aldosterone antagonists Need efficacious drugs Need targets other than frequently mentioned Patient QoL decreases visits, but still see need have on renal function that do not result in the neurohormonal desired measure as they lose the ability to for other therapies hypotension pathway; perform daily tasks that reduce mortality O V E R V I E W C A R D I A C C A N D I D A T E S S K E L E T A L C A N D I D A T E S C O R P O R A T E P R O F I L E 7

Significant Unmet Need in HCM Current therapies do not target underlying disease Current medical HCM is an inherited Surgical intervention therapy does not target cardiovascular disease not permanent solution underlying disease 1 in 500 have genetic mutation Invasive therapy to reduce Indirect mechanisms of action with septal thickness is effective systemic side effects 1 in 3200 have HCM Surgical myectomy or Variable efficacy, often inadequate Subset of patients have percutaneous ablation progressive symptoms, atrial fibrillation, stroke, sudden death O V E R V I E W C A R D I A C C A N D I D A T E S S K E L E T A L C A N D I D A T E S C O R P O R A T E P R O F I L E 8Significant Unmet Need in HCM Current therapies do not target underlying disease Current medical HCM is an inherited Surgical intervention therapy does not target cardiovascular disease not permanent solution underlying disease 1 in 500 have genetic mutation Invasive therapy to reduce Indirect mechanisms of action with septal thickness is effective systemic side effects 1 in 3200 have HCM Surgical myectomy or Variable efficacy, often inadequate Subset of patients have percutaneous ablation progressive symptoms, atrial fibrillation, stroke, sudden death O V E R V I E W C A R D I A C C A N D I D A T E S S K E L E T A L C A N D I D A T E S C O R P O R A T E P R O F I L E 8

Pipeline of Novel Muscle-Directed Drug Candidates Research Pre-Clinical Phase 1 Phase 2 Phase 3 CARDIAC MUSCLE Omecamtiv Mecarbil (Heart Failure) AMGEN COLLABORATION CK-274 (HCM) CK-271 AMG 594 (Heart Failure, other) AMGEN COLLABORATION SKELETAL MUSCLE Reldesemtiv CK-601 Additional Skeletal Muscle Activators ASTELLAS COLLABORATION OTHER Myosin-Targeted Muscle Biology Directed Research Troponin-Targeted Research Investigational products – not approved as safe or effective for any indication O V E R V I E W C A R D I A C C A N D I D A T E S S K E L E T A L C A N D I D A T E S C O R P O R A T E P R O F I L E 9Pipeline of Novel Muscle-Directed Drug Candidates Research Pre-Clinical Phase 1 Phase 2 Phase 3 CARDIAC MUSCLE Omecamtiv Mecarbil (Heart Failure) AMGEN COLLABORATION CK-274 (HCM) CK-271 AMG 594 (Heart Failure, other) AMGEN COLLABORATION SKELETAL MUSCLE Reldesemtiv CK-601 Additional Skeletal Muscle Activators ASTELLAS COLLABORATION OTHER Myosin-Targeted Muscle Biology Directed Research Troponin-Targeted Research Investigational products – not approved as safe or effective for any indication O V E R V I E W C A R D I A C C A N D I D A T E S S K E L E T A L C A N D I D A T E S C O R P O R A T E P R O F I L E 9

Sarcomere Directed Drug Development CARDIAC MUSCLE Omecamtiv Mecarbil AMG 594 CK-274, CK-271 10Sarcomere Directed Drug Development CARDIAC MUSCLE Omecamtiv Mecarbil AMG 594 CK-274, CK-271 10

Sarcomere Directed Drug Development Cardiac muscle The sarcomere is a molecular structure found in skeletal and cardiac muscle that enables cardiac myocytes to contract and generate force Troponin Activate Activate Inhibit Inhibit AMG 594 Omecamtiv CK-274 CK-271 (Cardiac) Mecarbil (Cardiac) (Cardiac) Myosin (Cardiac) Tropomyosin Actin Calcium Thin filament ATP Myosin Myosin head lever arm Thick filament 11Sarcomere Directed Drug Development Cardiac muscle The sarcomere is a molecular structure found in skeletal and cardiac muscle that enables cardiac myocytes to contract and generate force Troponin Activate Activate Inhibit Inhibit AMG 594 Omecamtiv CK-274 CK-271 (Cardiac) Mecarbil (Cardiac) (Cardiac) Myosin (Cardiac) Tropomyosin Actin Calcium Thin filament ATP Myosin Myosin head lever arm Thick filament 11

Omecamtiv Mecarbil: Novel Mechanism Approach O V E R V I E W C A R D I A C C A N D I D A T E S S K E L E T A L C A N D I D A T E S C O R P O R A T E P R O F I L E 12Omecamtiv Mecarbil: Novel Mechanism Approach O V E R V I E W C A R D I A C C A N D I D A T E S S K E L E T A L C A N D I D A T E S C O R P O R A T E P R O F I L E 12

Omecamtiv Mecarbil: Robust Clinical Trials Program Over 10,000 patient-years of exposure to omecamtiv mecarbil 11 7 Phase 1 Studies Phase 2 Studies 324 1,414 Subjects Enrolled Subjects Enrolled Well characterized safety, COSMIC-HF showed statistically tolerability and PK/PD data significant improvements in measures of cardiac function O V E R V I E W C A R D I A C C A N D I D A T E S S K E L E T A L C A N D I D A T E S C O R P O R A T E P R O F I L E 13Omecamtiv Mecarbil: Robust Clinical Trials Program Over 10,000 patient-years of exposure to omecamtiv mecarbil 11 7 Phase 1 Studies Phase 2 Studies 324 1,414 Subjects Enrolled Subjects Enrolled Well characterized safety, COSMIC-HF showed statistically tolerability and PK/PD data significant improvements in measures of cardiac function O V E R V I E W C A R D I A C C A N D I D A T E S S K E L E T A L C A N D I D A T E S C O R P O R A T E P R O F I L E 13

Dose-Dependent Increases in Cardiac Performance Pharmacodynamic results from COSMIC-HF SET Stroke Volume 8 40 p = 0.004 p = 0.022 p = 0.001 p < 0.001 35 6 30 4 25 2 20 15 0 10 -2 5 -4 0 Placebo 25 mg All PK Titration Placebo 25 mg All PK Titration LVFS LVEF 7.0 5 p = 0.025 p = 0.063 p = 0.017 p = 0.013 4 5.0 3 3.0 2 1.0 1 0 -1.0 Placebo 25 mg All PK Titration Placebo 25 mg All PK Titration LVEF, left ventricular ejection fraction; LVFS, left ventricular fractional shortening; SE, standard error; SET, systolic ejection time ; all p values are nominal without multiplicity adjustment. O V E R V I E W C A R D I A C C A N D I D A T E S S K E L E T A L C A N D I D A T E S C O R P O R A T E P R O F I L E 14 LS Mean (SE) Change (%) LS Mean (SE) Change (msec) LS Mean (SE) Change (%) LS Mean (SE) Change (mL)Dose-Dependent Increases in Cardiac Performance Pharmacodynamic results from COSMIC-HF SET Stroke Volume 8 40 p = 0.004 p = 0.022 p = 0.001 p < 0.001 35 6 30 4 25 2 20 15 0 10 -2 5 -4 0 Placebo 25 mg All PK Titration Placebo 25 mg All PK Titration LVFS LVEF 7.0 5 p = 0.025 p = 0.063 p = 0.017 p = 0.013 4 5.0 3 3.0 2 1.0 1 0 -1.0 Placebo 25 mg All PK Titration Placebo 25 mg All PK Titration LVEF, left ventricular ejection fraction; LVFS, left ventricular fractional shortening; SE, standard error; SET, systolic ejection time ; all p values are nominal without multiplicity adjustment. O V E R V I E W C A R D I A C C A N D I D A T E S S K E L E T A L C A N D I D A T E S C O R P O R A T E P R O F I L E 14 LS Mean (SE) Change (%) LS Mean (SE) Change (msec) LS Mean (SE) Change (%) LS Mean (SE) Change (mL)

Decreases in Physiology & Cardiac Risk Reductions in heart volume, oxygen demand & wall stress in COSMIC-HF LVEDV LVESV 10 0 5 -5 0 -10 -5 -10 -15 p = 0.062 p = 0.021 -15 -20 p = 0.019 p = 0.005 -20 -25 Placebo 25 mg All PK Titration Placebo 25 mg All PK Titration Heart Rate NT-proBNP 0 0 -1 P = 0.14 -300 -2 P = 0.007 -600 P = 0.007 -3 P = 0.087 -4 -900 P < 0.0001 P = 0.007 -5 -1200 4 8 12 16 20 Baseline Baseline 4 8 12 16 20 Weeks 2715 ± 258 pg/mL Weeks LVESV left ventricular end systolic volume; LVEDV left ventricular end diastolic volume All p values are nominal without multiplicity adjustment O V E R V I E W C A R D I A C C A N D I D A T E S S K E L E T A L C A N D I D A T E S C O R P O R A T E P R O F I L E 15 LS Mean (SE) Change (bpm) LS Mean (SE) Change (mL) LS Mean (SE) Change (pg/mL) LS Mean (SE) Change (mL)Decreases in Physiology & Cardiac Risk Reductions in heart volume, oxygen demand & wall stress in COSMIC-HF LVEDV LVESV 10 0 5 -5 0 -10 -5 -10 -15 p = 0.062 p = 0.021 -15 -20 p = 0.019 p = 0.005 -20 -25 Placebo 25 mg All PK Titration Placebo 25 mg All PK Titration Heart Rate NT-proBNP 0 0 -1 P = 0.14 -300 -2 P = 0.007 -600 P = 0.007 -3 P = 0.087 -4 -900 P < 0.0001 P = 0.007 -5 -1200 4 8 12 16 20 Baseline Baseline 4 8 12 16 20 Weeks 2715 ± 258 pg/mL Weeks LVESV left ventricular end systolic volume; LVEDV left ventricular end diastolic volume All p values are nominal without multiplicity adjustment O V E R V I E W C A R D I A C C A N D I D A T E S S K E L E T A L C A N D I D A T E S C O R P O R A T E P R O F I L E 15 LS Mean (SE) Change (bpm) LS Mean (SE) Change (mL) LS Mean (SE) Change (pg/mL) LS Mean (SE) Change (mL)

Neutral or Improved Measures of Diastolic Function Improved systolic function with no negative impact on diastolic function E/e’ IVRT 1 10 p<0.0001 p<0.0001 0 5 p=0.6718 0 -1 p=0.1355 -5 -2 Placebo PK Titration 25 mg Fixed Dose Placebo PK Titration 25 mg Fixed Dose TR Velocity Diastolic Filling Time 10 20 10 0 0 -10 -10 p=0.9767 p=0.877 -20 -20 p=0.221 p=0.0055 -30 -30 Placebo PK Titration Placebo PK Titration 25 mg Fixed Dose 25 mg Fixed Dose IVRT=isovolumic relaxation time TR=tricuspid regurgitation O V E R V I E W C A R D I A C C A N D I D A T E S S K E L E T A L C A N D I D A T E S C O R P O R A T E P R O F I L E 16 Change in TR velocity (cm/s) Change in E/e' ratio Change in IVRT (ms)Neutral or Improved Measures of Diastolic Function Improved systolic function with no negative impact on diastolic function E/e’ IVRT 1 10 p<0.0001 p<0.0001 0 5 p=0.6718 0 -1 p=0.1355 -5 -2 Placebo PK Titration 25 mg Fixed Dose Placebo PK Titration 25 mg Fixed Dose TR Velocity Diastolic Filling Time 10 20 10 0 0 -10 -10 p=0.9767 p=0.877 -20 -20 p=0.221 p=0.0055 -30 -30 Placebo PK Titration Placebo PK Titration 25 mg Fixed Dose 25 mg Fixed Dose IVRT=isovolumic relaxation time TR=tricuspid regurgitation O V E R V I E W C A R D I A C C A N D I D A T E S S K E L E T A L C A N D I D A T E S C O R P O R A T E P R O F I L E 16 Change in TR velocity (cm/s) Change in E/e' ratio Change in IVRT (ms)

Prognostic Implications: NT-proBNP and Remodeling Studies demonstrate correlation with cardiovascular outcomes Patients in PARADIGM-HF who had significant reductions in NT-proBNP had lower rates of CV death or heart failure 1 hospitalization Meta-analysis of drug/device therapies demonstrated association between LV remodeling and longer-term effects on 2 mortality in patients with LVD 1. Zile et al. JACC 2016; 68(22); 2425-2436 2. Kramer et al. JACC 2010;56(5):392-406 O V E R V I E W C A R D I A C C A N D I D A T E S S K E L E T A L C A N D I D A T E S C O R P O R A T E P R O F I L E 17Prognostic Implications: NT-proBNP and Remodeling Studies demonstrate correlation with cardiovascular outcomes Patients in PARADIGM-HF who had significant reductions in NT-proBNP had lower rates of CV death or heart failure 1 hospitalization Meta-analysis of drug/device therapies demonstrated association between LV remodeling and longer-term effects on 2 mortality in patients with LVD 1. Zile et al. JACC 2016; 68(22); 2425-2436 2. Kramer et al. JACC 2010;56(5):392-406 O V E R V I E W C A R D I A C C A N D I D A T E S S K E L E T A L C A N D I D A T E S C O R P O R A T E P R O F I L E 17

Pivotal Phase 3 Trial Completed Enrollment GALACTIC-HF continuing following first planned interim analysis Second interim analyses expected in Q1 2020 Overview Key Design Points • Dose optimization based on trough concentration of omecamtiv mecarbil Enrolled over 8,200 patients at ~1,000 sites in 35 countries at 2 weeks and 6 weeks • Starting Dose = 25 mg BID Primary Endpoint • Escalation (or not) at Week 4 to 37.5 mg or 50 mg BID based on plasma concentration of omecamtiv mecarbil at Week 2 Composite of time to CV death or first HF event*, • Recheck at Week 6, adjust dose downward if necessary whichever occurs first • Enroll patients from time of hospitalization to within 1 year of discharge Secondary Endpoints • In-hospital enrollment target is approximately 25% of total enrollment • Time to CV death • Stratify on randomization setting • Change in Kansas City Cardiomyopathy Questionnaire Total • Event driven with 90% power based on secondary endpoint of CV death Symptoms Score (KCCQ TSS) from baseline to Week 24 • Time to first HF hospitalization • Time to all-cause death *An HF event defined as the presentation of the subject for an urgent, unscheduled clinic/office/ED visit, or hospital admission, with a primary diagnosis of HF, where the patient exhibits new or worsening symptoms of HF on presentation, has objective evidence of new or worsening HF, and receives initiation or intensification of treatment specifically for HF (Hicks et al, 2015). Changes to oral diuretic therapy do not qualify as initiation or intensification of treatment. O V E R V I E W C A R D I A C C A N D I D A T E S S K E L E T A L C A N D I D A T E S C O R P O R A T E P R O F I L E 18Pivotal Phase 3 Trial Completed Enrollment GALACTIC-HF continuing following first planned interim analysis Second interim analyses expected in Q1 2020 Overview Key Design Points • Dose optimization based on trough concentration of omecamtiv mecarbil Enrolled over 8,200 patients at ~1,000 sites in 35 countries at 2 weeks and 6 weeks • Starting Dose = 25 mg BID Primary Endpoint • Escalation (or not) at Week 4 to 37.5 mg or 50 mg BID based on plasma concentration of omecamtiv mecarbil at Week 2 Composite of time to CV death or first HF event*, • Recheck at Week 6, adjust dose downward if necessary whichever occurs first • Enroll patients from time of hospitalization to within 1 year of discharge Secondary Endpoints • In-hospital enrollment target is approximately 25% of total enrollment • Time to CV death • Stratify on randomization setting • Change in Kansas City Cardiomyopathy Questionnaire Total • Event driven with 90% power based on secondary endpoint of CV death Symptoms Score (KCCQ TSS) from baseline to Week 24 • Time to first HF hospitalization • Time to all-cause death *An HF event defined as the presentation of the subject for an urgent, unscheduled clinic/office/ED visit, or hospital admission, with a primary diagnosis of HF, where the patient exhibits new or worsening symptoms of HF on presentation, has objective evidence of new or worsening HF, and receives initiation or intensification of treatment specifically for HF (Hicks et al, 2015). Changes to oral diuretic therapy do not qualify as initiation or intensification of treatment. O V E R V I E W C A R D I A C C A N D I D A T E S S K E L E T A L C A N D I D A T E S C O R P O R A T E P R O F I L E 18

Clinical Trial Overview Chronic HFrEF patients Omecamtiv mecarbil + SoC currently hospitalized Starting dose: 25mg PO BID for a primary reason of HF or with history of hospitalization or ER/ED admission for a primary Placebo + SoC reason of HF within 1 year Follow the same study procedures as OM group to ensure blinding Study Visits D1 W2 W4 W6 W8 W12 W24 W36 W48 Q16W PK assessment for dose adjustment PK assessment O V E R V I E W C A R D I A C C A N D I D A T E S S K E L E T A L C A N D I D A T E S C O R P O R A T E P R O F I L E 19 Screening Randomization 1:1 Stratified by Patient Subsets and Region EOSClinical Trial Overview Chronic HFrEF patients Omecamtiv mecarbil + SoC currently hospitalized Starting dose: 25mg PO BID for a primary reason of HF or with history of hospitalization or ER/ED admission for a primary Placebo + SoC reason of HF within 1 year Follow the same study procedures as OM group to ensure blinding Study Visits D1 W2 W4 W6 W8 W12 W24 W36 W48 Q16W PK assessment for dose adjustment PK assessment O V E R V I E W C A R D I A C C A N D I D A T E S S K E L E T A L C A N D I D A T E S C O R P O R A T E P R O F I L E 19 Screening Randomization 1:1 Stratified by Patient Subsets and Region EOS

Second Phase 3 Clinical Trial Underway Investigating effect of omecamtiv mecarbil on exercise tolerance Trial will enroll patients in 9 countries in North America and Europe Overview Key Design Points • Designed to enroll approximately 270 patients Change in peak VO2 on CPET from baseline to Week 20 • 20 weeks of treatment • 90% power Primary Endpoint • Patients must: • Change in total workload during CPET from baseline to Week 20 • Have LVEF ≤35 percent • Change in ventilatory efficiency (VE/VCO2 slope) during CPET from baseline to Week 20 • Be New York Heart Association (NYHA) • Change in average daily activity units measured over 2 weeks from baseline to Week 18-20 heart failure class II or III • Have reduced exercise capacity compared Explanatory Endpoints to age matched controls • Patients randomized 2:1 to omecamtiv mecarbil • Change from baseline to Week 20 in oxygen uptake efficiency slope (VO2/logVE slope), ventilatory threshold (by the V-slope method), VO2 recovery kinetics, percent predicted pVO2, • Starting dose at 25 mg twice daily, titrated to 25, and exercise duration 37.5 or 50 mg twice daily based on the same PK- • Change from baseline in average daily activity units at Week 6-8 and Week 12-14 guided dosing regimen used in GALACTIC-HF • Change from baseline in KCCQ Total Symptom Score and sub-domains from baseline to Week 20 VO2 = Oxygen Uptake; CPET = Cardio-Pulmonary Exercise Testing; VE = Ventilatory Efficiency O V E R V I E W C A R D I A C C A N D I D A T E S S K E L E T A L C A N D I D A T E S C O R P O R A T E P R O F I L E 20Second Phase 3 Clinical Trial Underway Investigating effect of omecamtiv mecarbil on exercise tolerance Trial will enroll patients in 9 countries in North America and Europe Overview Key Design Points • Designed to enroll approximately 270 patients Change in peak VO2 on CPET from baseline to Week 20 • 20 weeks of treatment • 90% power Primary Endpoint • Patients must: • Change in total workload during CPET from baseline to Week 20 • Have LVEF ≤35 percent • Change in ventilatory efficiency (VE/VCO2 slope) during CPET from baseline to Week 20 • Be New York Heart Association (NYHA) • Change in average daily activity units measured over 2 weeks from baseline to Week 18-20 heart failure class II or III • Have reduced exercise capacity compared Explanatory Endpoints to age matched controls • Patients randomized 2:1 to omecamtiv mecarbil • Change from baseline to Week 20 in oxygen uptake efficiency slope (VO2/logVE slope), ventilatory threshold (by the V-slope method), VO2 recovery kinetics, percent predicted pVO2, • Starting dose at 25 mg twice daily, titrated to 25, and exercise duration 37.5 or 50 mg twice daily based on the same PK- • Change from baseline in average daily activity units at Week 6-8 and Week 12-14 guided dosing regimen used in GALACTIC-HF • Change from baseline in KCCQ Total Symptom Score and sub-domains from baseline to Week 20 VO2 = Oxygen Uptake; CPET = Cardio-Pulmonary Exercise Testing; VE = Ventilatory Efficiency O V E R V I E W C A R D I A C C A N D I D A T E S S K E L E T A L C A N D I D A T E S C O R P O R A T E P R O F I L E 20

Clinical Trial Overview Omecamtiv mecarbil + SoC Starting dose 25mg BID; titrated by PK to 25, 37.5 or 50 mg BID Subjects with chronic HFrEF and reduced exercise capacity Placebo + SoC “Titrated” to maintain study blind Study Visits Screen W-2 D1 W2 W4 W6 W8 W14 W20 W24 OM Concentration Dose Adjustment CPET Echocardiogram* Actigraphy *Screening echocardiogram is not required if an appropriate LVEF assessment has been performed within one year O V E R V I E W C A R D I A C C A N D I D A T E S S K E L E T A L C A N D I D A T E S C O R P O R A T E P R O F I L E 21 Screening Randomized 2:1 (omecamtiv mecarbil: placebo) End of StudyClinical Trial Overview Omecamtiv mecarbil + SoC Starting dose 25mg BID; titrated by PK to 25, 37.5 or 50 mg BID Subjects with chronic HFrEF and reduced exercise capacity Placebo + SoC “Titrated” to maintain study blind Study Visits Screen W-2 D1 W2 W4 W6 W8 W14 W20 W24 OM Concentration Dose Adjustment CPET Echocardiogram* Actigraphy *Screening echocardiogram is not required if an appropriate LVEF assessment has been performed within one year O V E R V I E W C A R D I A C C A N D I D A T E S S K E L E T A L C A N D I D A T E S C O R P O R A T E P R O F I L E 21 Screening Randomized 2:1 (omecamtiv mecarbil: placebo) End of Study

Commercial Opportunity for New Heart Failure Therapy Projected to reach between $1.5-2B in sales in 2019; Analysts expect $3-5B in peak annual sales ® Entresto Global Product Sales (M) US Ex-US 1,208m 430 421 1,028m 357 318 507m 271 239 200 185 128 110 84 Q1 Q2 Q3 Q4 Q1 Q2 Q3 Q4 Q1 Q2 Q3 2017 2018 2019 *As with all products in Phase 3, the product profile achieved by omecamtiv mecarbil in GALACTIC-HF is required to provide a better understanding of the expected revenue. Source: Novartis public quarterly results presentations O V E R V I E W C A R D I A C C A N D I D A T E S S K E L E T A L C A N D I D A T E S C O R P O R A T E P R O F I L E 22Commercial Opportunity for New Heart Failure Therapy Projected to reach between $1.5-2B in sales in 2019; Analysts expect $3-5B in peak annual sales ® Entresto Global Product Sales (M) US Ex-US 1,208m 430 421 1,028m 357 318 507m 271 239 200 185 128 110 84 Q1 Q2 Q3 Q4 Q1 Q2 Q3 Q4 Q1 Q2 Q3 2017 2018 2019 *As with all products in Phase 3, the product profile achieved by omecamtiv mecarbil in GALACTIC-HF is required to provide a better understanding of the expected revenue. Source: Novartis public quarterly results presentations O V E R V I E W C A R D I A C C A N D I D A T E S S K E L E T A L C A N D I D A T E S C O R P O R A T E P R O F I L E 22

Commercial Readiness for Omecamtiv Mecarbil Multiple workstreams in progress to prepare for successful commercial launch Determine areas of Cultivate advocacy Educate heart failure Assess impact for differentiation for heart failure market value proposition for HCPs patients O V E R V I E W C A R D I A C C A N D I D A T E S S K E L E T A L C A N D I D A T E S C O R P O R A T E P R O F I L E 23Commercial Readiness for Omecamtiv Mecarbil Multiple workstreams in progress to prepare for successful commercial launch Determine areas of Cultivate advocacy Educate heart failure Assess impact for differentiation for heart failure market value proposition for HCPs patients O V E R V I E W C A R D I A C C A N D I D A T E S S K E L E T A L C A N D I D A T E S C O R P O R A T E P R O F I L E 23

Collaborations & Agreements Amgen Collaboration Royalty Monetization Purchase Option: 2006 Exercise Option Ex-Japan: 2009 Royalty Pharma paid $100M for 4.5% royalty on worldwide sales of omecamtiv mecarbil: 2017 Expanded to Include Japan/Purchase Equity: 2013 Received >$220M over 13 Years Commercialization: • Royalty rate may increase up to Amgen responsible Cytokinetics gains right additional 1% associated with timing of for development and to co-promote omecamtiv • Cytokinetics may receive escalating US approval commercialization subject double-digit royalties mecarbil, if approved, in • Cytokinetics agreed to exercise option to Cytokinetics’ institutional care settings • Cytokinetics to co-fund Phase 3 to co-invest $40M in Ph 3 development participation rights* in North America, with development program program in exchange for up to reimbursement from incremental 4% royalty on increasing • Co-fund enables co-promote NA Cytokinetics could Amgen for certain sales worldwide sales outside of Japan earn over $600 mm in • Cytokinetics reimbursed for certain force activities milestone payments • Cytokinetics retains right to receive sales force activities >$600M in additional potential milestone Joint commercial payments and escalating double-digit operating team responsible royalties that may exceed 20% on tiered for commercialization worldwide sales outside Japan; lower program royalty rate in Japan *Servier has a sub-license from Amgen to commercialize omecamtiv mecarbil in Europe and certain other countries. O V E R V I E W C A R D I A C C A N D I D A T E S S K E L E T A L C A N D I D A T E S C O R P O R A T E P R O F I L E 24Collaborations & Agreements Amgen Collaboration Royalty Monetization Purchase Option: 2006 Exercise Option Ex-Japan: 2009 Royalty Pharma paid $100M for 4.5% royalty on worldwide sales of omecamtiv mecarbil: 2017 Expanded to Include Japan/Purchase Equity: 2013 Received >$220M over 13 Years Commercialization: • Royalty rate may increase up to Amgen responsible Cytokinetics gains right additional 1% associated with timing of for development and to co-promote omecamtiv • Cytokinetics may receive escalating US approval commercialization subject double-digit royalties mecarbil, if approved, in • Cytokinetics agreed to exercise option to Cytokinetics’ institutional care settings • Cytokinetics to co-fund Phase 3 to co-invest $40M in Ph 3 development participation rights* in North America, with development program program in exchange for up to reimbursement from incremental 4% royalty on increasing • Co-fund enables co-promote NA Cytokinetics could Amgen for certain sales worldwide sales outside of Japan earn over $600 mm in • Cytokinetics reimbursed for certain force activities milestone payments • Cytokinetics retains right to receive sales force activities >$600M in additional potential milestone Joint commercial payments and escalating double-digit operating team responsible royalties that may exceed 20% on tiered for commercialization worldwide sales outside Japan; lower program royalty rate in Japan *Servier has a sub-license from Amgen to commercialize omecamtiv mecarbil in Europe and certain other countries. O V E R V I E W C A R D I A C C A N D I D A T E S S K E L E T A L C A N D I D A T E S C O R P O R A T E P R O F I L E 24

AMG 594: Cardiac Troponin Activator Advancing through Phase 1: Potential for HFrEF and other indications Troponin • Intended to improve ventricular systolic function in patients with heart failure • Preclinical results support the potential for best-in-class safety and efficacy • Projected once daily dosing O V E R V I E W C A R D I A C C A N D I D A T E S S K E L E T A L C A N D I D A T E S C O R P O R A T E P R O F I L E 25AMG 594: Cardiac Troponin Activator Advancing through Phase 1: Potential for HFrEF and other indications Troponin • Intended to improve ventricular systolic function in patients with heart failure • Preclinical results support the potential for best-in-class safety and efficacy • Projected once daily dosing O V E R V I E W C A R D I A C C A N D I D A T E S S K E L E T A L C A N D I D A T E S C O R P O R A T E P R O F I L E 25

AMG 594: Nested SAD and MAD in Healthy Subjects Randomized, placebo-controlled, double-blind, Objectives Endpoints multi-part, single center study Safety and tolerability AEs, laboratories, cardiac markers, ECGs • Part 1: 5 ascending single oral doses (SAD) Pharmacokinetics C , T , AUC max max • Part 2: 3 ascending multiple oral doses (MAD) Pharmacodynamics LVEF, LVFS, LVOT-VTI, SET • ~64 healthy subjects overall TBD TBD Cohort 3 Cohort 5 Cohort 2 Cohort 4 Cohort 1 Cohort 3 Cohort 2 SAD: Ascending Single Doses MAD: Ascending Multiple Doses (7 days) Cohort 1 O V E R V I E W C A R D I A C C A N D I D A T E S S K E L E T A L C A N D I D A T E S C O R P O R A T E P R O F I L E 26AMG 594: Nested SAD and MAD in Healthy Subjects Randomized, placebo-controlled, double-blind, Objectives Endpoints multi-part, single center study Safety and tolerability AEs, laboratories, cardiac markers, ECGs • Part 1: 5 ascending single oral doses (SAD) Pharmacokinetics C , T , AUC max max • Part 2: 3 ascending multiple oral doses (MAD) Pharmacodynamics LVEF, LVFS, LVOT-VTI, SET • ~64 healthy subjects overall TBD TBD Cohort 3 Cohort 5 Cohort 2 Cohort 4 Cohort 1 Cohort 3 Cohort 2 SAD: Ascending Single Doses MAD: Ascending Multiple Doses (7 days) Cohort 1 O V E R V I E W C A R D I A C C A N D I D A T E S S K E L E T A L C A N D I D A T E S C O R P O R A T E P R O F I L E 26

CK-274: Next-In-Class Cardiac Myosin Inhibitor Potential treatments for patients with HCM • Discovered by company scientists independent of collaborations • Selective allosteric inhibitor of cardiac myosin • Potential in vivo pharmacodynamic advantages related to distinctive binding site • No inhibition of smooth muscle myosin observed Myosin • Clear pharmacokinetic/pharmacodynamic (PK/PD) relationship observed • Projected once daily dosing to reach steady state rapidly in patients • Shallow dose response curve translated to favorable therapeutic window in healthy volunteers O V E R V I E W C A R D I A C C A N D I D A T E S S K E L E T A L C A N D I D A T E S C O R P O R A T E P R O F I L E 27CK-274: Next-In-Class Cardiac Myosin Inhibitor Potential treatments for patients with HCM • Discovered by company scientists independent of collaborations • Selective allosteric inhibitor of cardiac myosin • Potential in vivo pharmacodynamic advantages related to distinctive binding site • No inhibition of smooth muscle myosin observed Myosin • Clear pharmacokinetic/pharmacodynamic (PK/PD) relationship observed • Projected once daily dosing to reach steady state rapidly in patients • Shallow dose response curve translated to favorable therapeutic window in healthy volunteers O V E R V I E W C A R D I A C C A N D I D A T E S S K E L E T A L C A N D I D A T E S C O R P O R A T E P R O F I L E 27

SAD & MAD Results Support Progression to Phase 2 CK-274 was well tolerated in healthy participants: no SAEs* SAD Pharmacokinetics Appeared Steady-State Appeared Evident After Generally Dose Proportional 14 Days of Dosing Steady-state 600 150 attained 5 mg qd x 14d 10 mg qy x 14d 3,000 400 100 2,000 Through samples only 200 50 1,000 Last dose 0 0 0 1 3 10 25 40 50 1 3 10 25 40 50 0 2 4 6 8 10 12 14 16 18 20 Dose (mg) Dose (mg) Nominal Day *No SAEs and no clinically meaningful changes in vital signs, ECGs, or laboratory tests Data points represent mean ± standard error of the mean Cmax = maximum drug plasma concentration; AUC = area under the plasma concentration curve; SAD = single ascending dose; d = day; qd = once daily O V E R V I E W C A R D I A C C A N D I D A T E S S K E L E T A L C A N D I D A T E S C O R P O R A T E P R O F I L E 28 C (ng/mL) max AUG (ng/mL) 24 CK-274 (ng/mL)SAD & MAD Results Support Progression to Phase 2 CK-274 was well tolerated in healthy participants: no SAEs* SAD Pharmacokinetics Appeared Steady-State Appeared Evident After Generally Dose Proportional 14 Days of Dosing Steady-state 600 150 attained 5 mg qd x 14d 10 mg qy x 14d 3,000 400 100 2,000 Through samples only 200 50 1,000 Last dose 0 0 0 1 3 10 25 40 50 1 3 10 25 40 50 0 2 4 6 8 10 12 14 16 18 20 Dose (mg) Dose (mg) Nominal Day *No SAEs and no clinically meaningful changes in vital signs, ECGs, or laboratory tests Data points represent mean ± standard error of the mean Cmax = maximum drug plasma concentration; AUC = area under the plasma concentration curve; SAD = single ascending dose; d = day; qd = once daily O V E R V I E W C A R D I A C C A N D I D A T E S S K E L E T A L C A N D I D A T E S C O R P O R A T E P R O F I L E 28 C (ng/mL) max AUG (ng/mL) 24 CK-274 (ng/mL)

CY 6011: MAD Pharmacokinetic Parameters Shallow Exposure-Response Relationship Observed Half-Life of CK-274 at Steady-State Preclinically Appears to Have Translated to Humans, was ~81 hours (3.4 days) On Average May Enable Flexible Dose Optimization in Humans PK/PD Relationship of CK-274 for Ejection Fraction (LVEF) Dose (n) 5 mg (6) 7.5 mg (6) 10 mg (6) 100 C (ng/mL) 69 (23.2%) 148 (39.5% 141 (19.7%) max 80 Graphs show LVEF as a function of exposure; data t (h) 2.75 (1.5–4) 1.0 (0.5–5) 2.5 (0.5–3) 60 max points represent observed values in dogs and 40 AUG (ng•h/mL) 1,321 (23.0%) 2,518 (25.8%) 2,631 (22.8%) 24 humans. 20 Decrease in LVEF Dog t (h) 86.3 (11.9) 76.9 (14.5) 79.7 (14.1) as function of 1/2 Human exposure is 0 similar in humans and dogs. AR 4.71 4.5 4.79 0.0001 0.001 0.010 0.100 1.000 Free Plasma Concentration (µmoI/L) *Except data for tmax shown as median (minimum-maximum), and t½ shown as the arithmetic mean (standard deviation). AR (accumulation ratio) calculated as (AUC24 on Day 14 or 17)/(AUC24 on Day 1). %CV = percent coefficient of variation; Cmax = maximum plasma concentration; AUC24 = area under the plasma concentration curve; MAD = multiple ascending dose; t½ = apparent plasma terminal elimination half-life; tmax = time to maximum observed plasma concentration. O V E R V I E W C A R D I A C C A N D I D A T E S S K E L E T A L C A N D I D A T E S C O R P O R A T E P R O F I L E 29 PK Parameter, Geometric Mean (%CV)* LVEF (% of Baseline)CY 6011: MAD Pharmacokinetic Parameters Shallow Exposure-Response Relationship Observed Half-Life of CK-274 at Steady-State Preclinically Appears to Have Translated to Humans, was ~81 hours (3.4 days) On Average May Enable Flexible Dose Optimization in Humans PK/PD Relationship of CK-274 for Ejection Fraction (LVEF) Dose (n) 5 mg (6) 7.5 mg (6) 10 mg (6) 100 C (ng/mL) 69 (23.2%) 148 (39.5% 141 (19.7%) max 80 Graphs show LVEF as a function of exposure; data t (h) 2.75 (1.5–4) 1.0 (0.5–5) 2.5 (0.5–3) 60 max points represent observed values in dogs and 40 AUG (ng•h/mL) 1,321 (23.0%) 2,518 (25.8%) 2,631 (22.8%) 24 humans. 20 Decrease in LVEF Dog t (h) 86.3 (11.9) 76.9 (14.5) 79.7 (14.1) as function of 1/2 Human exposure is 0 similar in humans and dogs. AR 4.71 4.5 4.79 0.0001 0.001 0.010 0.100 1.000 Free Plasma Concentration (µmoI/L) *Except data for tmax shown as median (minimum-maximum), and t½ shown as the arithmetic mean (standard deviation). AR (accumulation ratio) calculated as (AUC24 on Day 14 or 17)/(AUC24 on Day 1). %CV = percent coefficient of variation; Cmax = maximum plasma concentration; AUC24 = area under the plasma concentration curve; MAD = multiple ascending dose; t½ = apparent plasma terminal elimination half-life; tmax = time to maximum observed plasma concentration. O V E R V I E W C A R D I A C C A N D I D A T E S S K E L E T A L C A N D I D A T E S C O R P O R A T E P R O F I L E 29 PK Parameter, Geometric Mean (%CV)* LVEF (% of Baseline)

Phase 2 Clinical Trial Design Phase 2 clinical trial open to enrollment CK-3773274 + SoC Patients with 2 symptomatic oHCM, and resting or provoked LVOT 1 gradient ≥ 50 mmHg Placebo + SoC Study Visits Screen W-1 D1 W2 W4 W6 W9 W10 W12 W14 Ambulatory Cardiac Monitoring PK Echocardiogram Dose Titration O V E R V I E W C A R D I A C C A N D I D A T E S S K E L E T A L C A N D I D A T E S C O R P O R A T E P R O F I L E 30 Screening Randomization End of StudyPhase 2 Clinical Trial Design Phase 2 clinical trial open to enrollment CK-3773274 + SoC Patients with 2 symptomatic oHCM, and resting or provoked LVOT 1 gradient ≥ 50 mmHg Placebo + SoC Study Visits Screen W-1 D1 W2 W4 W6 W9 W10 W12 W14 Ambulatory Cardiac Monitoring PK Echocardiogram Dose Titration O V E R V I E W C A R D I A C C A N D I D A T E S S K E L E T A L C A N D I D A T E S C O R P O R A T E P R O F I L E 30 Screening Randomization End of Study

CK-274: Clinical Development Plan for HCM Phase 1 Phase 2 Phase 3 Safety, PK & PD Proof of Concept, Dose Finding Pivotal Studies SAD & MAD oHCM patients oHCM patients Healthy Placebo Controlled Exercise Endpoint (peak VO2) Volunteers Echocardiography Endpoints IND Filed NDA Safe & tolerated dose NDA: Potential for approval based on a single Improved LVOT gradient with desired PD effects Ph3 study with an exercise endpoint Extension study Long-term safety & efficacy Proof of activity in nHCM pts Pivotal study in nHCM O V E R V I E W C A R D I A C C A N D I D A T E S S K E L E T A L C A N D I D A T E S C O R P O R A T E P R O F I L E 31CK-274: Clinical Development Plan for HCM Phase 1 Phase 2 Phase 3 Safety, PK & PD Proof of Concept, Dose Finding Pivotal Studies SAD & MAD oHCM patients oHCM patients Healthy Placebo Controlled Exercise Endpoint (peak VO2) Volunteers Echocardiography Endpoints IND Filed NDA Safe & tolerated dose NDA: Potential for approval based on a single Improved LVOT gradient with desired PD effects Ph3 study with an exercise endpoint Extension study Long-term safety & efficacy Proof of activity in nHCM pts Pivotal study in nHCM O V E R V I E W C A R D I A C C A N D I D A T E S S K E L E T A L C A N D I D A T E S C O R P O R A T E P R O F I L E 31

Sarcomere Directed Drug Development SKELETAL MUSCLE Reldesemtiv CK-601 32Sarcomere Directed Drug Development SKELETAL MUSCLE Reldesemtiv CK-601 32

Sarcomere Directed Drug Development Skeletal muscle The sarcomere is a molecular structure found in skeletal and cardiac muscle that enables cardiac myocytes to contract and generate force Troponin Activate Activate Reldesemtiv CK-601 (Skeletal) (Skeletal) Tropomyosin Actin Calcium Thin filament ATP Myosin Myosin head lever arm Thick filament O V E R V I E W C A R D I A C C A N D I D A T E S S K E L E T A L C A N D I D A T E S C O R P O R A T E P R O F I L E 33Sarcomere Directed Drug Development Skeletal muscle The sarcomere is a molecular structure found in skeletal and cardiac muscle that enables cardiac myocytes to contract and generate force Troponin Activate Activate Reldesemtiv CK-601 (Skeletal) (Skeletal) Tropomyosin Actin Calcium Thin filament ATP Myosin Myosin head lever arm Thick filament O V E R V I E W C A R D I A C C A N D I D A T E S S K E L E T A L C A N D I D A T E S C O R P O R A T E P R O F I L E 33

Significant Unmet Need in ALS No approved muscle directed therapies Prevalence* Incidence* • Average 3-5 year mortality U.K. U.K. • Current therapies provide modest benefit 4,300 1,200 France • Initial symptoms include: limb weakness, France 4,300 slurred speech, swallowing issues 1,200 • Average age at diagnosis is 55-65 U.S. Germany U.S. 6,300 Germany 5,700 25,000 • Death most commonly due to 1,600 respiratory failure *Cytokinetics estimates based on proprietary market research Source: NIH National Institute of Neurological Disorders and Stroke, ALS Fact Sheet O V E R V I E W C A R D I A C C A N D I D A T E S S K E L E T A L C A N D I D A T E S C O R P O R A T E P R O F I L E 34Significant Unmet Need in ALS No approved muscle directed therapies Prevalence* Incidence* • Average 3-5 year mortality U.K. U.K. • Current therapies provide modest benefit 4,300 1,200 France • Initial symptoms include: limb weakness, France 4,300 slurred speech, swallowing issues 1,200 • Average age at diagnosis is 55-65 U.S. Germany U.S. 6,300 Germany 5,700 25,000 • Death most commonly due to 1,600 respiratory failure *Cytokinetics estimates based on proprietary market research Source: NIH National Institute of Neurological Disorders and Stroke, ALS Fact Sheet O V E R V I E W C A R D I A C C A N D I D A T E S S K E L E T A L C A N D I D A T E S C O R P O R A T E P R O F I L E 34

Phase 2 Clinical Trial in ALS Results presented at American Academy of Neurology 2019 Double-Blind, Placebo-Controlled: 12 weeks Placebo (n = 110) Parallel group, dose ranging study enrolled 458 patients with ALS in the US and 150 mg BID (n = 110) Canada, evaluating change Screening Follow-up from baseline in the percent 2 weeks 4 weeks predicted slow vital 300 mg BID (n = 110) capacity (SVC) at 12 weeks of treatment with reldesemtiv or placebo 450 mg BID (n = 110) Randomization 1:1:1:1 End of Dosing O V E R V I E W C A R D I A C C A N D I D A T E S S K E L E T A L C A N D I D A T E S C O R P O R A T E P R O F I L E 35Phase 2 Clinical Trial in ALS Results presented at American Academy of Neurology 2019 Double-Blind, Placebo-Controlled: 12 weeks Placebo (n = 110) Parallel group, dose ranging study enrolled 458 patients with ALS in the US and 150 mg BID (n = 110) Canada, evaluating change Screening Follow-up from baseline in the percent 2 weeks 4 weeks predicted slow vital 300 mg BID (n = 110) capacity (SVC) at 12 weeks of treatment with reldesemtiv or placebo 450 mg BID (n = 110) Randomization 1:1:1:1 End of Dosing O V E R V I E W C A R D I A C C A N D I D A T E S S K E L E T A L C A N D I D A T E S C O R P O R A T E P R O F I L E 35

Primary Endpoint: SVC Change from baseline in percent predicted SVC at week 12 -6.46 -4.97 -4.62 -4.58 0 -1 -2 -3 Primary Analysis* P = 0.11 -4 for weighted -5 dose-response relationship -6 -7 * -8 -9 Placebo 150 mg BID 300 mg BID 450 mg BID *Based on Mixed Model for Repeated Measures (MMRM) with the contrasts of (-5, -1, 3, 3) for placebo, reldesemtiv 150 mg, 300 mg and 450 mg BID, respectively O V E R V I E W C A R D I A C C A N D I D A T E S S K E L E T A L C A N D I D A T E S C O R P O R A T E P R O F I L E 36 Percent Predicted SVC Change From Baseline at Week 12 (95% CI)Primary Endpoint: SVC Change from baseline in percent predicted SVC at week 12 -6.46 -4.97 -4.62 -4.58 0 -1 -2 -3 Primary Analysis* P = 0.11 -4 for weighted -5 dose-response relationship -6 -7 * -8 -9 Placebo 150 mg BID 300 mg BID 450 mg BID *Based on Mixed Model for Repeated Measures (MMRM) with the contrasts of (-5, -1, 3, 3) for placebo, reldesemtiv 150 mg, 300 mg and 450 mg BID, respectively O V E R V I E W C A R D I A C C A N D I D A T E S S K E L E T A L C A N D I D A T E S C O R P O R A T E P R O F I L E 36 Percent Predicted SVC Change From Baseline at Week 12 (95% CI)

Change From Baseline: All Active vs Placebo* Results support progression to potential Phase 3 clinical trial SVC Change From Baseline ALSFRS-R Change From Baseline (All Active vs Placebo) (All Active vs Placebo) 0.0 0.0 *P = 0.10 *P = 0.01 LS Mean (SE) Difference LS Mean (SE) in Change of % Difference in Change -1.0 Predicted SVC 1.7 (1.1) of ALSFRS-R 0.9 (0.3) -2.5 -2.0 -5.0 -3.0 Relative reduction of 27% Relative reduction of 25% in decline of percent predicted in drop of ALSFRS-R -7.5 -4.0 SVC compared with placebo compared to placebo -5.0 -10.0 12 Weeks of Dosing Off Drug 12 Weeks of Dosing Off Drug Week 16/ Week 8 Week 16/ Week 8 Baseline Week 2 Week 4 Week 12 Baseline Week 2 Week 4 Week 12 Follow-up Follow-up Visit Visit Study Treatment: Placebo All Active Study Treatment: Placebo All Active *post hoc analysis FORTITUDE-ALS did not achieve statistical significance, but patients on all dose groups of reldesemtiv declined less than patients on placebo O V E R V I E W C A R D I A C C A N D I D A T E S S K E L E T A L C A N D I D A T E S C O R P O R A T E P R O F I L E 37 LS Mean (±SE) of Change in Percent Predicted SVC From Baseline LS Mean (±SE) of Change in Functional Rating Scale – Revised (ALSFRS-R) From BaselineChange From Baseline: All Active vs Placebo* Results support progression to potential Phase 3 clinical trial SVC Change From Baseline ALSFRS-R Change From Baseline (All Active vs Placebo) (All Active vs Placebo) 0.0 0.0 *P = 0.10 *P = 0.01 LS Mean (SE) Difference LS Mean (SE) in Change of % Difference in Change -1.0 Predicted SVC 1.7 (1.1) of ALSFRS-R 0.9 (0.3) -2.5 -2.0 -5.0 -3.0 Relative reduction of 27% Relative reduction of 25% in decline of percent predicted in drop of ALSFRS-R -7.5 -4.0 SVC compared with placebo compared to placebo -5.0 -10.0 12 Weeks of Dosing Off Drug 12 Weeks of Dosing Off Drug Week 16/ Week 8 Week 16/ Week 8 Baseline Week 2 Week 4 Week 12 Baseline Week 2 Week 4 Week 12 Follow-up Follow-up Visit Visit Study Treatment: Placebo All Active Study Treatment: Placebo All Active *post hoc analysis FORTITUDE-ALS did not achieve statistical significance, but patients on all dose groups of reldesemtiv declined less than patients on placebo O V E R V I E W C A R D I A C C A N D I D A T E S S K E L E T A L C A N D I D A T E S C O R P O R A T E P R O F I L E 37 LS Mean (±SE) of Change in Percent Predicted SVC From Baseline LS Mean (±SE) of Change in Functional Rating Scale – Revised (ALSFRS-R) From Baseline

Subgroup Analyses* ALSFRS-R Total Score Percent Predicted SVC No. of Patients LSM Difference No. of Patients LSM Difference (pbo/reldesemtiv) (95% Cl) Estimate P value (pbo/reldesemtiv) (95% Cl) Estimate P value Percent predicted SVC at baseline Percent predicted SVC at baseline <80 38/102 1.037 0.5935 <80 43/109 1.588 0.0089 ≥80 52/187 2.135 0.0834 ≥80 57/196 0.264 0.5296 ALSFRS-R total score at baseline ALSFRS-R total score at baseline <Median (38.0) 43/118 2.886 0.1.41 <Median (38.0) 48/129 1.107 0.0585 ≥Median (38.0) 47/171 0.451 0.7146 ≥Median (38.0) 52/176 0.685 0.0987 ALSAQ-5 total score at baseline ALSAQ-5 total score at baseline <150 49/159 0.568 0.6689 <150 52/164 0.266 0.5025 ≥150 41/130 3.489 0.0287 ≥150 48/141 1.598 0.0055 Anatomic site of disease onset Anatomic site of disease onset Limb 73/234 2.309 0.0448 Limb 80/245 0.872 0.0279 Bulbar 17/55 -0.027 0.9923 Bulbar 20/60 0.861 0.2194 Time since ALS symptom onset Time since ALS symptom onset <2 Years 50/188 0.530 0.7211 <2 Years 56/199 1.422 0.0025 ≥2 Years 40/101 3.640 0.0094 ≥2 Years 44/106 0.475 0.3439 Time since ALS diagnosis Time since ALS diagnosis <1 Year 65/210 0.819 0.5263 <1 Year 71/225 1.123 0.0101 ≥1 Year 25/79 4.237 0.0172 ≥1 Year 29/80 0.359 0.5350 <6 Months 39/130 1.230 0.4538 <6 Months 42/137 1.359 0.0154 ≥6 Months 51/159 2.285 0.1024 ≥6 Months 58/168 0.566 0.1820 Pre-study rate of disease progression Pre-study rate of disease progression (ALSFRS-R total score reduction per month) (ALSFRS-R total score reduction per month) st st 1 tertile ≤(0.3667) 29/107 0.663 0.6361 1 tertile ≤(0.3667) 32/110 0.389 0.4298 nd nd 2 tertile > (0.3667) – (0.6673) 35/94 2.960 0.0976 2 tertile > (0.3667) – (0.6673) 38/99 0.987 0.0665 rd rd 3 tertile (0.6673) 26/88 1.620 0.4597 3 tertile (0.6673) 30/96 1.733 0.0177 -15 -10 -5 0 5 10 15 -5 -2.5 0 2.5 5 Favors Placebo Favors Treatment Favors Placebo Favors Treatment *FORTITUDE-ALS did not achieve statistical significance, but patients on all dose groups of reldesemtiv declined less than patients on placebo O V E R V I E W C A R D I A C C A N D I D A T E S S K E L E T A L C A N D I D A T E S C O R P O R A T E P R O F I L E 38Subgroup Analyses* ALSFRS-R Total Score Percent Predicted SVC No. of Patients LSM Difference No. of Patients LSM Difference (pbo/reldesemtiv) (95% Cl) Estimate P value (pbo/reldesemtiv) (95% Cl) Estimate P value Percent predicted SVC at baseline Percent predicted SVC at baseline <80 38/102 1.037 0.5935 <80 43/109 1.588 0.0089 ≥80 52/187 2.135 0.0834 ≥80 57/196 0.264 0.5296 ALSFRS-R total score at baseline ALSFRS-R total score at baseline <Median (38.0) 43/118 2.886 0.1.41 <Median (38.0) 48/129 1.107 0.0585 ≥Median (38.0) 47/171 0.451 0.7146 ≥Median (38.0) 52/176 0.685 0.0987 ALSAQ-5 total score at baseline ALSAQ-5 total score at baseline <150 49/159 0.568 0.6689 <150 52/164 0.266 0.5025 ≥150 41/130 3.489 0.0287 ≥150 48/141 1.598 0.0055 Anatomic site of disease onset Anatomic site of disease onset Limb 73/234 2.309 0.0448 Limb 80/245 0.872 0.0279 Bulbar 17/55 -0.027 0.9923 Bulbar 20/60 0.861 0.2194 Time since ALS symptom onset Time since ALS symptom onset <2 Years 50/188 0.530 0.7211 <2 Years 56/199 1.422 0.0025 ≥2 Years 40/101 3.640 0.0094 ≥2 Years 44/106 0.475 0.3439 Time since ALS diagnosis Time since ALS diagnosis <1 Year 65/210 0.819 0.5263 <1 Year 71/225 1.123 0.0101 ≥1 Year 25/79 4.237 0.0172 ≥1 Year 29/80 0.359 0.5350 <6 Months 39/130 1.230 0.4538 <6 Months 42/137 1.359 0.0154 ≥6 Months 51/159 2.285 0.1024 ≥6 Months 58/168 0.566 0.1820 Pre-study rate of disease progression Pre-study rate of disease progression (ALSFRS-R total score reduction per month) (ALSFRS-R total score reduction per month) st st 1 tertile ≤(0.3667) 29/107 0.663 0.6361 1 tertile ≤(0.3667) 32/110 0.389 0.4298 nd nd 2 tertile > (0.3667) – (0.6673) 35/94 2.960 0.0976 2 tertile > (0.3667) – (0.6673) 38/99 0.987 0.0665 rd rd 3 tertile (0.6673) 26/88 1.620 0.4597 3 tertile (0.6673) 30/96 1.733 0.0177 -15 -10 -5 0 5 10 15 -5 -2.5 0 2.5 5 Favors Placebo Favors Treatment Favors Placebo Favors Treatment *FORTITUDE-ALS did not achieve statistical significance, but patients on all dose groups of reldesemtiv declined less than patients on placebo O V E R V I E W C A R D I A C C A N D I D A T E S S K E L E T A L C A N D I D A T E S C O R P O R A T E P R O F I L E 38

Post-Hoc Analyses Inform Potential Path Forward Change From Baseline in ALSFRS-R Probability of No New DME* Over Time by Progressor Tertiles With Treatment With Reldesemtiv DME (Durable Medical Equipment): Manual wheelchair, power wheelchair, NIV, Augmentative Language Device, PEG Time (weeks) 0 1.0 0 2 4 6 8 10 12 14 -0.5 0.9 -1 -1.5 0.8 Patients on -2 reldesemtiv had significantly lower risk -2.5 (38%) of agreeing to receive DME 0.7 compared to placebo Treatment difference -3 1.15; P = 0.0112 -3.5 0.6 -4 342 328 300 264 114 104 93 80 -4.5 0 4 8 12 Weeks on Treatment SP reldesemtiv combined (n=117) SP placebo (n=35) MP + FP reldesemtiv combined (n=227) MP + FP placebo (n=79) All Active Placebo O V E R V I E W C A R D I A C C A N D I D A T E S S K E L E T A L C A N D I D A T E S C O R P O R A T E P R O F I L E 39 LS mean change from baseline in ALSFRS-R Probability of No New DMEPost-Hoc Analyses Inform Potential Path Forward Change From Baseline in ALSFRS-R Probability of No New DME* Over Time by Progressor Tertiles With Treatment With Reldesemtiv DME (Durable Medical Equipment): Manual wheelchair, power wheelchair, NIV, Augmentative Language Device, PEG Time (weeks) 0 1.0 0 2 4 6 8 10 12 14 -0.5 0.9 -1 -1.5 0.8 Patients on -2 reldesemtiv had significantly lower risk -2.5 (38%) of agreeing to receive DME 0.7 compared to placebo Treatment difference -3 1.15; P = 0.0112 -3.5 0.6 -4 342 328 300 264 114 104 93 80 -4.5 0 4 8 12 Weeks on Treatment SP reldesemtiv combined (n=117) SP placebo (n=35) MP + FP reldesemtiv combined (n=227) MP + FP placebo (n=79) All Active Placebo O V E R V I E W C A R D I A C C A N D I D A T E S S K E L E T A L C A N D I D A T E S C O R P O R A T E P R O F I L E 39 LS mean change from baseline in ALSFRS-R Probability of No New DME

Sarcomere Directed Therapies CORPORATE PROFILE 40Sarcomere Directed Therapies CORPORATE PROFILE 40

Achieve regulatory approvals for at least two drugs arising from our pipeline Build commercial capabilities to market and sell our medicines reflective of their innovation and value VISION Generate sustainable and growing Our vision is to be the revenues from product sales leading muscle biology biopharma company that meaningfully improves the lives of patients with diseases of impaired muscle function through access to our Double our development pipeline to pioneering medicines Leading with Science, include ten therapeutic programs As always, we will support disease advocacy groups elevating the patient voice and live by our values of Expand our discovery platform to muscle integrity, fairness and compassion in all that we do. energetics, growth and metabolism Be the science-driven company people want to join and partner with O V E R V I E W C A R D I A C C A N D I D A T E S S K E L E T A L C A N D I D A T E S C O R P O R A T E P R O F I L E 41Achieve regulatory approvals for at least two drugs arising from our pipeline Build commercial capabilities to market and sell our medicines reflective of their innovation and value VISION Generate sustainable and growing Our vision is to be the revenues from product sales leading muscle biology biopharma company that meaningfully improves the lives of patients with diseases of impaired muscle function through access to our Double our development pipeline to pioneering medicines Leading with Science, include ten therapeutic programs As always, we will support disease advocacy groups elevating the patient voice and live by our values of Expand our discovery platform to muscle integrity, fairness and compassion in all that we do. energetics, growth and metabolism Be the science-driven company people want to join and partner with O V E R V I E W C A R D I A C C A N D I D A T E S S K E L E T A L C A N D I D A T E S C O R P O R A T E P R O F I L E 41

Cytokinetics Financing History in millions Upfront Cash, Option, R&D Financing Equity & Milestones Reimbursement Total Private Investors (VCs) $116 $116 IPO $94 $94 Public Post-IPO/Other $420 $420 Investors Term Loan $45 $45 Convertible Debt (net)* $120.5 $120.5 Capital raised: $165.5 $630 $795.5 combination of Astellas $10 $130 $92 $232 strategic partners Amgen $43 $145 $40 $228 and investors Royalty Pharma $10 $90 – $100 GSK $24 $22 $33 $79 Strategic AstraZeneca – – $2 $2 Partners MyoKardia – – $2 $2 & Grants Global Blood – – $2 $2 Grants (ALS Assoc/NINDS/other) – $6 – $6 $87 $393 $171 $651 *Net of fees and expenses O V E R V I E W C A R D I A C C A N D I D A T E S S K E L E T A L C A N D I D A T E S C O R P O R A T E P R O F I L E 42Cytokinetics Financing History in millions Upfront Cash, Option, R&D Financing Equity & Milestones Reimbursement Total Private Investors (VCs) $116 $116 IPO $94 $94 Public Post-IPO/Other $420 $420 Investors Term Loan $45 $45 Convertible Debt (net)* $120.5 $120.5 Capital raised: $165.5 $630 $795.5 combination of Astellas $10 $130 $92 $232 strategic partners Amgen $43 $145 $40 $228 and investors Royalty Pharma $10 $90 – $100 GSK $24 $22 $33 $79 Strategic AstraZeneca – – $2 $2 Partners MyoKardia – – $2 $2 & Grants Global Blood – – $2 $2 Grants (ALS Assoc/NINDS/other) – $6 – $6 $87 $393 $171 $651 *Net of fees and expenses O V E R V I E W C A R D I A C C A N D I D A T E S S K E L E T A L C A N D I D A T E S C O R P O R A T E P R O F I L E 42

Balance Sheet & Financial Guidance Ended 2019 with 2-3 years of cash based on 2019 guidance* Q3 2019 Condensed Balance Sheet 2019 Financial Guidance As of 9/30/19 in millions in millions Total Total $28 – 32 Cash and investments $166.0 Cash Revenue $110 – 115 Cash Operating Expenses Other assets $21.4 Net ~ $90 Total Assets $187.4 $44.8 Debt $137.7 Liability related to sale of future royalties $24.8 Other liabilities Total Liabilities $207.3 Working capital $155.0 Accumulated deficit -$834.4 Stockholders' Equity (Deficit) -$19.9 Basic Shares Outstanding 58.6 *Q3 balance sheet doesn’t include $120M raised in convertible debt financing in Q4 2019 O V E R V I E W C A R D I A C C A N D I D A T E S S K E L E T A L C A N D I D A T E S C O R P O R A T E P R O F I L E 43Balance Sheet & Financial Guidance Ended 2019 with 2-3 years of cash based on 2019 guidance* Q3 2019 Condensed Balance Sheet 2019 Financial Guidance As of 9/30/19 in millions in millions Total Total $28 – 32 Cash and investments $166.0 Cash Revenue $110 – 115 Cash Operating Expenses Other assets $21.4 Net ~ $90 Total Assets $187.4 $44.8 Debt $137.7 Liability related to sale of future royalties $24.8 Other liabilities Total Liabilities $207.3 Working capital $155.0 Accumulated deficit -$834.4 Stockholders' Equity (Deficit) -$19.9 Basic Shares Outstanding 58.6 *Q3 balance sheet doesn’t include $120M raised in convertible debt financing in Q4 2019 O V E R V I E W C A R D I A C C A N D I D A T E S S K E L E T A L C A N D I D A T E S C O R P O R A T E P R O F I L E 43

Upcoming 2020 Milestones Expect Second Interim Analyses from Conduct Commercial File IND and Initiate GALACTIC-HF in Q1 Complete Enrollment in Readiness & Develop Conduct Phase 1 Study of METEORIC-HF Co-Promotion Plan for REDWOOD-HCM CK-271 in 1H Expect Topline Results Omecamtiv Mecarbil from GALACTIC-HF in Q4 Prepare for Potential Complete Phase 1 Advance CK-601 in Phase 3 Clinical Trial SAD/MAD Study of IND-Enabling Studies of Reldesemtiv in AMG 594 in 2H Patients with ALS O V E R V I E W C A R D I A C C A N D I D A T E S S K E L E T A L C A N D I D A T E S C O R P O R A T E P R O F I L E 44Upcoming 2020 Milestones Expect Second Interim Analyses from Conduct Commercial File IND and Initiate GALACTIC-HF in Q1 Complete Enrollment in Readiness & Develop Conduct Phase 1 Study of METEORIC-HF Co-Promotion Plan for REDWOOD-HCM CK-271 in 1H Expect Topline Results Omecamtiv Mecarbil from GALACTIC-HF in Q4 Prepare for Potential Complete Phase 1 Advance CK-601 in Phase 3 Clinical Trial SAD/MAD Study of IND-Enabling Studies of Reldesemtiv in AMG 594 in 2H Patients with ALS O V E R V I E W C A R D I A C C A N D I D A T E S S K E L E T A L C A N D I D A T E S C O R P O R A T E P R O F I L E 44

Sarcomere Directed Therapies THANK YOU John, diagnosed with heart failure Jillian, diagnosed with HCM Chuck, diagnosed with ALSSarcomere Directed Therapies THANK YOU John, diagnosed with heart failure Jillian, diagnosed with HCM Chuck, diagnosed with ALS